Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (405)	1/23/2001 12:07:18 PM
From: tuck	Read Replies (1) \| Respond to of 1784

IPO waters pretty muddy so far for biotechs. NetGenics couldn't do it, and had to cut its workforce because it wouldn't have the funding it anticipated. ThirdWave has started its roadshow, and interest looks thin. Deal might not get done. Check the story at genomeweb.com. XGEN is not exactly a bioinformatics company, but it could be affected by this. Development stage companies just don't seem to be in right now. Cheers, Tuck

To: tuck who wrote (405)	1/24/2001 2:35:51 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1784

Tuck..... still haven't looked at S-1, but it's number one on "to do" list, maybe just before or after close today. Also haven't had time to review comments of others, if any.......... Xenogen Enters Into a Research Agreement With Pfizer - Program to Study Effects of Genetic Modifications - ALAMEDA, Calif., Jan. 24 /PRNewswire/ -- Xenogen Corporation announced that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to develop new methods of identifying potential therapeutic drug targets with the use of transgenic mice. "We look forward to working with Pfizer in the area of understanding genetic modifications and their impact on health and well-being," said Pamela Reilly Contag, PhD., president and co-CEO of Xenogen Corporation. " We believe that analyzing gene function is key to choosing targets for drug discovery. It is our hope that this collaboration with Pfizer will expedite data-mining processes that may ultimately lead to new drugs and therapies." The agreement terminates in December 2003, but can be extended at Pfizer's option for two successive one-year periods. About Xenogen Corporation Xenogen Corporation is a leader in the field of real-time in vivo imaging, providing the pharmaceutical industry with proprietary technologies, products and services to enable real-time in vivo monitoring to identify drug leads for clinical development. In addition to pharmaceutical development, Xenogen believes that its technology has broad applications in other fields, including biomedical research and toxicology testing in the chemical industry. Xenogen has recently entered into a series of agreements with leading pharmaceutical and biotechnology companies. Recent Xenogen milestones include the granting of a commercial license to a company of Novartis Research Foundation and the granting of evaluation licenses to Organon, AstraZeneca, Cell Genesys, Cubist Pharmaceuticals and DuPont Pharmaceuticals. This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including risks cited in the risk factors sections of Xenogen's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Xenogen disclaims an intent or obligation to update these forward- looking statements. For more information, visit the Xenogen web site at xenogen.com SOURCE Xenogen Corporation Web Site: xenogen.com hillandknowlton.com